Our Speakers



Our Speakers

Shahram Salek-Ardakani
Shahram Salek-Ardakani

Alessandra Cesano
Alessandra Cesano

Chief Medical Officer, NanoString Technologies

Carsten Corvey
Carsten Corvey

Group Leader, Global Bio therapeutics Sanofi, Germany

Chris Allen
Chris Allen

Sr. Field Application Specialist Thermo Fisher Scientific, UK

Christine Schuberth-Wagner
Christine Schuberth-Wagner

Senior Vice President, Research Rigontec GmbH, Germany

Christoph Sachse
Christoph Sachse

Site Head Berlin, NMI TT Pharmaservices Natural Sciences and Medical Institute at the University of Tübingen, Germany

Christophe Henry
Christophe Henry

Project Lead, Translational Medicine Sanofi, France

Craig Malcolm
Craig Malcolm

Strategic Collaborations Manager Promega UK Ltd, UK

Dr Ahuva Nissim
Dr Ahuva Nissim

Reader in Antibody and Therapeutic Engineering Biochemical Pharmacology Barts and The London, Queen Mary's School of Medicine and Dentistry , ohn Vane Science Centre, UK

Dr. A. Graham Pockley
Dr. A. Graham Pockley

Associate Director, John van Geest Cancer Research Centre, Nottingham Trent University, London UK

Dr. Charles Dumontet
Dr. Charles Dumontet

Adjunct Director of the Cancer Research Center of Lyon, Chair of the Research Council of the Hospices Civils de Lyon Cancer Research Center of Lyon, France

Dr. Christian Ostheimer
Dr. Christian Ostheimer

Dept. of Radiation Oncology-University Hospital Halle (UKH) Martin Luther University Halle-Wittenberg, Germany

Dr. Darren Schofield
Dr. Darren Schofield

Senior Research Scientist, MedImmune

Dr. Helmout Modjtahedi
Dr. Helmout Modjtahedi

Professor of Cancer Biology, Director of Cancer Research Group, Kingston University London

Dr. Jeanette Leusen
Dr. Jeanette Leusen

Associate professor and Head Immunotherapy group Laboratory for Translational Immunology University Medical Centre Utrecht, The Netherlands

Dr. Jens Lohrmann
Dr. Jens Lohrmann

Senior Global Program Manager - Translational Clinical Oncology Novartis, Switzerland

Dr. Johanna Olweus
Dr. Johanna Olweus

Director-K.G. Jebsen Centre for Cancer Immunotherapy Head-Department of Immunology- Institute for Cancer Research Oslo University Hospital Radium University of Oslo, Norway

Dr. Lioudmila Tchistiakova
Dr. Lioudmila Tchistiakova

Senior Director-Global Biotherapeutic Technologies Pfizer BioTx, Maryland USA

Dr. Lolke de Haan
Dr. Lolke de Haan

Director of Toxicology MedImmune, Cambridge, UK

Dr. Maria Groves
Dr. Maria Groves

Head of CRUK-MEDI Alliance Laboratory, MedImmune

Dr. Mark Creighton-Gutteridge
Dr. Mark Creighton-Gutteridge

Head of Discovery and New Technologies, Oncology Cell Therapy Unit, GlaxoSmithKline, UK

Dr. Martina Seiffert
Dr. Martina Seiffert

Team Leader CLL Tumor Microenvironment German Cancer Research Centre

Dr. Matthias Friedrich
Dr. Matthias Friedrich

Scientific Director, Nonclinical Development AMGEN Research (Munich) GmbH

Dr. Maxim  Shevtsov
Dr. Maxim Shevtsov

Professor – Immunotherapy Group Klinikum rechts der Isar Technische Universität München, Germany

Dr. Nicolas Fischer
Dr. Nicolas Fischer

Head of Research, Novimmune

Dr. Randolf Kerschbaumer
Dr. Randolf Kerschbaumer

Director R&D, Antibody Technology Shire, Austria

Dr. Robert Hawkins
Dr. Robert Hawkins

Director and Professor of Medical Oncology University of Manchester and Christie Hospital.

Dr. Roy Baynes
Dr. Roy Baynes

Senior Vice President and Head, Global Clinical Development, Chief Medical Officer, MSD

Merck Research Laboratories

Dr. Sine Reker Hadrup
Dr. Sine Reker Hadrup

Associate Professor and section Head Immunology and Vaccinology Technical University of Denmark, Denmark

Dr. Sonia Quaratino
Dr. Sonia Quaratino

Global Clinical Program Leader, Novartis, Switzerland

Dr. Sophia N. Karagiannis
Dr. Sophia N. Karagiannis

Head of Cancer Antibody Discovery and Immunotherapy Division of Genetics and Molecular Medicine, Kings College London

Dr. Thierry Wurch
Dr. Thierry Wurch

Global Director - Antibody Projects Servier, France

Dr. Yvonne Andersson
Dr. Yvonne Andersson

Scientist and Project leader: Anti-cancer therapy with immunotoxin Oslo University Hospital, Norway

Ivan Diaz Padilla
Ivan Diaz Padilla

Global Clinical Leader Global Drug Development, Oncology Novartis Pharma AG, Switzerland

Mahendra Deonarain
Mahendra Deonarain

Chief Science and Operating Officer Antikor Biopharma Ltd, UK

Marlon J. Hinner
Marlon J. Hinner

Director, Immuno-Oncology Pieris Pharmaceuticals, Germany

Martin Schwill
Martin Schwill

Phd- Department of Biochemistry-Laboratory of Prof. A. Plueckthun University of Zurich

Matthew Baker
Matthew Baker

VP, Immunology & Oncology Celentyx Ltd,UK

Nathalie Faye
Nathalie Faye

Medical Director Median Technologies

Payal Roychoudhury
Payal Roychoudhury

Field Applications Scientist, Maxcyte, Maryland USA

Prof. Angus Dalgleish
Prof. Angus Dalgleish

Professor of Oncology, Chair of oncology -Institute of Infection and Immunity St. George’s University of London, UK

Prof. Dr. Andre Frenzel
Prof. Dr. Andre Frenzel

Senior antibody engineering expert- Institute of Biochemistry, Biotechnology and Bioinformatics Technische Universität Braunschweig, Germany

Prof. Dr. Gabriele Multhoff
Prof. Dr. Gabriele Multhoff

Klinikum Rechts der Isar -Department of Radiation Oncology and Radiation Technical University of Munich, Germany

Prof. Dr. Thomas Valerius
Prof. Dr. Thomas Valerius

Medical Department II, Section on Stem Cell and Immunotherapy, University Hospital Schleswig – Kiel University, Germany

Prof. Hardev Pandha
Prof. Hardev Pandha

Professor of Medical Oncology- Tumour Immunology University of Surrey, UK

Prof. Kris Thielemans
Prof. Kris Thielemans

Head-Laboratory of Molecular & Cellular Therapy, Vrije Universiteit Brussel (VUB), Faculty of Medicine & Pharmacy

Prof. Lindy Durrant
Prof. Lindy Durrant

Cancer Immunotherapy, Faculty of Medicine & Health Sciences Academic Clinical Oncology, The University of Nottingham

Prof. Roland Kontermann
Prof. Roland Kontermann

Professor and Deputy Director -Biomedical Engineering, Institute of Cell Biology and Immunology University of Stuttgart, Germany

Steve Anderton
Steve Anderton

Chief Scientific Officer, Aquila BioMedical, UK


Loading...